Real-World Effectiveness Study of Nirmatrelvir-Ritonavir or Molnupiravir in Hospitalized Unvaccinated Patients with Chronic Respiratory Diseases and Moderate COVID-19 at Presentation

Wang Chun Kwok,1 Terence Chi Chun Tam,1 James Chung Man Ho,1 David Chi Leung Lam,1 Mary Sau-Man Ip,1 Pak Leung Ho2 1Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of China; 2Department of Microbiology and...

Full description

Bibliographic Details
Main Authors: Kwok WC, Tam TCC, Ho JCM, Lam DCL, Ip MSM, Ho PL
Format: Article
Language:English
Published: Dove Medical Press 2024-01-01
Series:International Journal of COPD
Subjects:
Online Access:https://www.dovepress.com/real-world-effectiveness-study-of-nirmatrelvir-ritonavir-or-molnupirav-peer-reviewed-fulltext-article-COPD
_version_ 1827384388030038016
author Kwok WC
Tam TCC
Ho JCM
Lam DCL
Ip MSM
Ho PL
author_facet Kwok WC
Tam TCC
Ho JCM
Lam DCL
Ip MSM
Ho PL
author_sort Kwok WC
collection DOAJ
description Wang Chun Kwok,1 Terence Chi Chun Tam,1 James Chung Man Ho,1 David Chi Leung Lam,1 Mary Sau-Man Ip,1 Pak Leung Ho2 1Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of China; 2Department of Microbiology and Carol Yu Centre for Infection, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of ChinaCorrespondence: Pak Leung Ho, Department of Microbiology and Carol Yu Centre for Infection, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of China, Tel +852-2255-2584, Fax +852 2855 1241, Email plho@hku.hkIntroduction: Nirmatrelvir-ritonavir (NMV-r) and molnupiravir (MOL) were developed as out-patient anti-viral for mild COVID-19. There was limited data on their role in treating COVID-19 for hospitalized patients, especially among adult patients who are unvaccinated and had chronic respiratory diseases.Methods: A territory-wide retrospective study was conducted in Hong Kong to compare the efficacy of NMV-r and MOL against COVID-19 in unvaccinated adult patients with asthma, chronic obstructive pulmonary disease, bronchiectasis and interstitial lung diseases presenting with moderate COVID-19 from 16th February 2022 to 15th March 2023.Results: A total of 1354 patients were included, 738 received NMV-r and 616 received MOL. NMV-r was more effective in reducing 90-day mortality with adjusted hazard ratios (aHR) of 0.508 (95% confidence interval [CI] = 0.314– 0.822, p = 0.006). Patients who received NMV-r also had significantly shorter length of stay (LOS) than those receiving MOL, with median LOS of 4 (Interquartile range [IQR] = 2– 7) for NMV-r and 6 (IQR = 3– 10) for MOL (p-value < 0.001). There was no statistically significant difference in the development of respiratory failure and severe respiratory failure in the two groups.Discussion: NMV-r was more effective than MOL among unvaccinated adults with chronic respiratory diseases who were hospitalized for moderate COVID-19 without hypoxaemia on admission.Keywords: asthma, COPD, bronchiectasis, interstitial lung disease, molnupiravir, nirmatrelvir-ritonavir, COVID-19
first_indexed 2024-03-08T14:54:51Z
format Article
id doaj.art-f25b008d5dbe493aaa7a0af967f1b363
institution Directory Open Access Journal
issn 1178-2005
language English
last_indexed 2024-03-08T14:54:51Z
publishDate 2024-01-01
publisher Dove Medical Press
record_format Article
series International Journal of COPD
spelling doaj.art-f25b008d5dbe493aaa7a0af967f1b3632024-01-10T18:05:59ZengDove Medical PressInternational Journal of COPD1178-20052024-01-01Volume 19778689612Real-World Effectiveness Study of Nirmatrelvir-Ritonavir or Molnupiravir in Hospitalized Unvaccinated Patients with Chronic Respiratory Diseases and Moderate COVID-19 at PresentationKwok WCTam TCCHo JCMLam DCLIp MSMHo PLWang Chun Kwok,1 Terence Chi Chun Tam,1 James Chung Man Ho,1 David Chi Leung Lam,1 Mary Sau-Man Ip,1 Pak Leung Ho2 1Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of China; 2Department of Microbiology and Carol Yu Centre for Infection, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of ChinaCorrespondence: Pak Leung Ho, Department of Microbiology and Carol Yu Centre for Infection, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of China, Tel +852-2255-2584, Fax +852 2855 1241, Email plho@hku.hkIntroduction: Nirmatrelvir-ritonavir (NMV-r) and molnupiravir (MOL) were developed as out-patient anti-viral for mild COVID-19. There was limited data on their role in treating COVID-19 for hospitalized patients, especially among adult patients who are unvaccinated and had chronic respiratory diseases.Methods: A territory-wide retrospective study was conducted in Hong Kong to compare the efficacy of NMV-r and MOL against COVID-19 in unvaccinated adult patients with asthma, chronic obstructive pulmonary disease, bronchiectasis and interstitial lung diseases presenting with moderate COVID-19 from 16th February 2022 to 15th March 2023.Results: A total of 1354 patients were included, 738 received NMV-r and 616 received MOL. NMV-r was more effective in reducing 90-day mortality with adjusted hazard ratios (aHR) of 0.508 (95% confidence interval [CI] = 0.314– 0.822, p = 0.006). Patients who received NMV-r also had significantly shorter length of stay (LOS) than those receiving MOL, with median LOS of 4 (Interquartile range [IQR] = 2– 7) for NMV-r and 6 (IQR = 3– 10) for MOL (p-value < 0.001). There was no statistically significant difference in the development of respiratory failure and severe respiratory failure in the two groups.Discussion: NMV-r was more effective than MOL among unvaccinated adults with chronic respiratory diseases who were hospitalized for moderate COVID-19 without hypoxaemia on admission.Keywords: asthma, COPD, bronchiectasis, interstitial lung disease, molnupiravir, nirmatrelvir-ritonavir, COVID-19https://www.dovepress.com/real-world-effectiveness-study-of-nirmatrelvir-ritonavir-or-molnupirav-peer-reviewed-fulltext-article-COPDasthmacopdbronchiectasisinterstitial lung diseasemolnupiravirnirmatrelvir-ritonavircovid-19
spellingShingle Kwok WC
Tam TCC
Ho JCM
Lam DCL
Ip MSM
Ho PL
Real-World Effectiveness Study of Nirmatrelvir-Ritonavir or Molnupiravir in Hospitalized Unvaccinated Patients with Chronic Respiratory Diseases and Moderate COVID-19 at Presentation
International Journal of COPD
asthma
copd
bronchiectasis
interstitial lung disease
molnupiravir
nirmatrelvir-ritonavir
covid-19
title Real-World Effectiveness Study of Nirmatrelvir-Ritonavir or Molnupiravir in Hospitalized Unvaccinated Patients with Chronic Respiratory Diseases and Moderate COVID-19 at Presentation
title_full Real-World Effectiveness Study of Nirmatrelvir-Ritonavir or Molnupiravir in Hospitalized Unvaccinated Patients with Chronic Respiratory Diseases and Moderate COVID-19 at Presentation
title_fullStr Real-World Effectiveness Study of Nirmatrelvir-Ritonavir or Molnupiravir in Hospitalized Unvaccinated Patients with Chronic Respiratory Diseases and Moderate COVID-19 at Presentation
title_full_unstemmed Real-World Effectiveness Study of Nirmatrelvir-Ritonavir or Molnupiravir in Hospitalized Unvaccinated Patients with Chronic Respiratory Diseases and Moderate COVID-19 at Presentation
title_short Real-World Effectiveness Study of Nirmatrelvir-Ritonavir or Molnupiravir in Hospitalized Unvaccinated Patients with Chronic Respiratory Diseases and Moderate COVID-19 at Presentation
title_sort real world effectiveness study of nirmatrelvir ritonavir or molnupiravir in hospitalized unvaccinated patients with chronic respiratory diseases and moderate covid 19 at presentation
topic asthma
copd
bronchiectasis
interstitial lung disease
molnupiravir
nirmatrelvir-ritonavir
covid-19
url https://www.dovepress.com/real-world-effectiveness-study-of-nirmatrelvir-ritonavir-or-molnupirav-peer-reviewed-fulltext-article-COPD
work_keys_str_mv AT kwokwc realworldeffectivenessstudyofnirmatrelvirritonavirormolnupiravirinhospitalizedunvaccinatedpatientswithchronicrespiratorydiseasesandmoderatecovid19atpresentation
AT tamtcc realworldeffectivenessstudyofnirmatrelvirritonavirormolnupiravirinhospitalizedunvaccinatedpatientswithchronicrespiratorydiseasesandmoderatecovid19atpresentation
AT hojcm realworldeffectivenessstudyofnirmatrelvirritonavirormolnupiravirinhospitalizedunvaccinatedpatientswithchronicrespiratorydiseasesandmoderatecovid19atpresentation
AT lamdcl realworldeffectivenessstudyofnirmatrelvirritonavirormolnupiravirinhospitalizedunvaccinatedpatientswithchronicrespiratorydiseasesandmoderatecovid19atpresentation
AT ipmsm realworldeffectivenessstudyofnirmatrelvirritonavirormolnupiravirinhospitalizedunvaccinatedpatientswithchronicrespiratorydiseasesandmoderatecovid19atpresentation
AT hopl realworldeffectivenessstudyofnirmatrelvirritonavirormolnupiravirinhospitalizedunvaccinatedpatientswithchronicrespiratorydiseasesandmoderatecovid19atpresentation